Home Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics
Article
Licensed
Unlicensed Requires Authentication

Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics

  • Tomomi Masuda and Eiji Miyoshi EMAIL logo
Published/Copyright: March 24, 2011

Abstract

Hepatocellular carcinomas (HCC) are the fifth most common tumor type and the third most common cause of cancer-related death worldwide. Some tumor markers for HCC, such as α-fetoprotein and des-γ-carboxyprothrombin, are used clinically. Recent advances in proteomics and glyco-proteomics might provide various types of novel tumor markers for HCC. While the clinical availability of these tumor markers is important, the molecular mechanisms underlying the production of tumor markers requires further clarification. Our group has investigated the glycobiology of tumor markers. In this review, we describe the impact of novel HCC markers and their possible implications for clinical use.


Corresponding author: Eiji Miyoshi, Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7 Yamada-oka, Suita 565-0871, Japan Phone/Fax: +81-6-6879-2590

Received: 2010-8-19
Accepted: 2010-12-27
Published Online: 2011-03-24
Published in Print: 2011-06-01

©2011 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Editors’ and Publisher’s Note
  2. CCLM Award for The Most Cited Paper Recently Published
  3. Reviews
  4. Some views on proteomics in diabetes
  5. Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics
  6. Minireviews
  7. Low-density lipoprotein receptor-related protein 1: new functions for an old molecule
  8. Could serum measurements of S100 proteins be reliable markers to predict recurrence in meningiomas?
  9. Opinion Paper
  10. Focusing on the clinical impact of standardization of creatinine measurements: a report by the EFCC Working Group on Creatinine Standardization
  11. General Clinical Chemistry and Laboratory Medicine
  12. Use of a fully automated immunoassay for celiac disease screening in a pediatric population
  13. Evaluation of four commercial biuret reagent kits of serum total protein by the American Association for Clinical Chemistry reference measurement procedure
  14. Renal function parameters during early and late recovery periods following an all-out 21-km run in trained adolescent runners
  15. Increased urinary neutrophil gelatinase associated lipocalin in urinary tract infections and leukocyturia
  16. The severity of pseudohyperkalaemia is not dependent upon the stage of chronic kidney disease: a prospective study
  17. Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies
  18. Perchlorate (Irenat®) may falsely lower measured ionised calcium
  19. Comparison of thyroglobulin antibody interference in first- and second-generation thyroglobulin immunoassays
  20. A case of consistent discrepancies between urine and blood human chorionic gonadotropin measurements
  21. Reference Values and Biological Variations
  22. Reference change values for monitoring dehydration
  23. Cancer Diagnostics
  24. Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis
  25. Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study
  26. Cardiovascular Diseases
  27. High-sensitivity troponin T improves the prognostic value of N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: results from the LURIC Study
  28. Letters to the Editor
  29. Results of a pilot external quality assessment study on free protoporphyrin in erythrocytes
  30. Trueness assessment of Korean nation-wide glucose proficiency testing
  31. Genetic polymorphism of cytochrome P450 1A1 in a northern Italian population: high frequency of the CYP1A1*2C allele
  32. Prestaining of PCR products with SYBR Green for agarose gel electrophoresis: advantages and limitations
  33. A bias in quantitative RT-PCR limit of detection is induced by the use of cancer cell lines in the molecular detection of circulating tumor cells
  34. Treatment of hepatitis B virus-associated membranous nephritis patients in Chinese: an open parallel controlled trial
  35. Evidence on the cause of false positive troponin I results with the Beckman AccuTnI method
  36. Cross-reactivity of insulin analogs with the Diasorin Liaison Insulin assay
  37. Improved turnaround time for neonatal hematology profile tests (complete blood count) using a new microcollection tube
  38. Erratum
  39. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes
Downloaded on 6.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.152/pdf
Scroll to top button